What Is Aprotinin Studied For? Research Areas, Per the Literature

Short answer: in the published literature, aprotinin appears most often in studies of blood loss and transfusion during surgery, in laboratory work describing how a broad protease inhibitor interacts with coagulation and inflammation pathways, in a smaller number of preclinical ischemia experiments, in one randomized trial in moderate COVID-19, and in safety reviews focused on hypersensitivity reactions. The sections below describe each research area, the type of study involved, and the population or model studied.

This page is not guidance. This page is for educational purposes only and is not medical advice; consult a licensed physician for any health question. Readers comparing peptide classes may also find the general overview at Are Peptides Safe? useful for context on how safety evidence is built.

What Aprotinin Is, in Research Terms

Aprotinin is a small polypeptide protease inhibitor of bovine origin. A 2001 review in The Annals of Thoracic Surgery characterised aprotinin as an inhibitor of serine proteases and set out the proposed antithrombotic and antiinflammatory mechanisms attributed to it in the surgical literature (PMID 11789829). Because it blocks several proteases rather than one target, researchers have examined it across coagulation, fibrinolysis and inflammatory cascades at once, which is part of why the literature on it is unusually broad for a single molecule (PMID 11789829).

Aprotinin has also served as a model protein in biophysics. A 2025 computational and theoretical study in Journal of Molecular Modeling used multiscale modelling of infrared spectra to follow the thermal denaturation process of aprotinin, an in silico investigation of protein structure rather than a study of any clinical effect (PMID 41045371).

Research Areas at a Glance

Surgical Bleeding and Transfusion Requirement

The largest body of aprotinin research sits in surgery. A 2001 clinical study in The British Journal of Oral and Maxillofacial Surgery examined patients undergoing orthognathic surgery and reported that aprotinin reduced blood loss and the need for transfusion in that population (PMID 11601817). That report is an example of the wider surgical question researchers have asked repeatedly: whether inhibiting plasmin and related proteases changes how much a patient bleeds during an operation (PMID 11789829).

A 2018 study in the Journal of Cardiothoracic and Vascular Anesthesia assessed the effectiveness and safety of aprotinin use specifically in thoracic aortic surgery, a setting where bleeding risk is high and the operative population is distinct from routine cardiac cases (PMID 29217251). A 2015 review in Anaesthesia revisited where aprotinin sits in the overall management of bleeding, summarising how the balance between haemostatic benefit and risk has been argued in the surgical literature (PMID 25440394).

These surgical studies share an important limitation for anyone reading the word "uses" broadly: they describe administration in a controlled operating-room setting by clinical teams, with monitoring, in patients undergoing specific procedures. They do not describe any other context (PMID 25440394).

Mechanism Research: Coagulation, Fibrinolysis and Inflammation

Mechanistic work has tried to explain why a protease inhibitor would affect bleeding at all. The 2001 Annals of Thoracic Surgery review laid out antithrombotic and antiinflammatory mechanisms of action proposed for aprotinin, linking protease inhibition to effects on both clot breakdown and inflammatory signalling during cardiac surgery (PMID 11789829).

A 2006 study in Acta Anaesthesiologica Scandinavica took a laboratory approach, using thrombelastography on plasma to characterise how aprotinin altered coagulation kinetics, and the researchers examined the role of Factor XI in those changes (PMID 16430537). Work of this type is in vitro: it measures clot formation in a device, not patient outcomes.

The Prothrombotic Question

A recurring mechanistic debate is whether inhibiting fibrinolysis tips the balance toward unwanted clotting. A 2001 article in Perfusion addressed that question directly under the title "Aprotinin: is it prothrombotic?", reviewing the arguments and evidence available at the time (PMID 11565895). A 2023 human study in Hormone and Metabolic Research approached a related endpoint and reported that aprotinin did not impair vascular function in patients undergoing coronary artery bypass graft surgery (PMID 36599358).

Infectious Disease: A Randomized COVID-19 Trial

Interest in aprotinin as a pan-protease inhibitor extended to viral illness, because some viruses depend on host proteases for entry. A 2022 randomized phase III study published in the European Journal of Clinical Investigation evaluated the safety and efficacy of aprotinin as a pan-protease inhibitor in adults with moderate COVID-19 (PMID 35342931). This is the clearest example in the verified citation set of aprotinin being studied outside the operating room, and the study design was a randomized controlled trial rather than an observational series (PMID 35342931).

Readers should note the scope: a single randomized trial in one defined patient group, in one phase of one pandemic illness, does not establish a general antiviral research area, and no other infectious disease evidence appears in the verified set (PMID 35342931).

Preclinical Ischemia Research

A 2021 experimental study in The Journal of Surgical Research investigated a synergistic effect of beta-alanine combined with aprotinin in a model of mesenteric ischemia, which is preclinical work in an experimental model rather than a human trial (PMID 33639373). Findings from a combination experiment in an ischemia model do not transfer to clinical practice, and no human follow-up for that combination appears among the verified papers (PMID 33639373).

Aprotinin Safety and Tolerability: What Studies Report

Safety is one of the most heavily documented aspects of aprotinin. A 2005 review in The Annals of Thoracic Surgery covered forty years of clinical aprotinin use and analysed 124 reported hypersensitivity reactions, making allergic and anaphylactic reaction the single best characterised adverse event in this literature (PMID 15680884). Because aprotinin is derived from bovine tissue, immune reactivity has been a central safety concern rather than an incidental one (PMID 15680884).

A 2007 review in the European Journal of Anaesthesiology, titled "Aprotinin; friend or foe?", surveyed the medical literature during a period of intense dispute about whether the haemostatic effects justified the risks reported in clinical studies (PMID 17105674). The 2015 Anaesthesia review returned to the same balance question when reassessing the place of aprotinin in bleeding management (PMID 25440394). Thrombosis risk was examined separately in the 2001 Perfusion review of whether aprotinin is prothrombotic (PMID 11565895), while the 2018 thoracic aortic surgery study assessed both effectiveness and safety in that surgical population (PMID 29217251).

Where the Evidence Is Weak, Preclinical Only, or Absent

Several topics commonly attached to the question "what is aprotinin used for" are not supported by the verified literature on this page. Stated plainly:

• General wellness, anti-ageing or performance contexts: no study in the verified set examined aprotinin for any such purpose, and the surgical and mechanistic papers are confined to clinical and laboratory bleeding and inflammation questions (PMID 11789829).
• Ischemia and organ protection: represented only by a preclinical combination experiment in a mesenteric ischemia model, with no human data in the verified set (PMID 33639373).
• Antiviral use beyond one trial: limited to a single randomized phase III study in moderate COVID-19 (PMID 35342931).
• Self-directed or non-clinical administration: no study in the verified set evaluated aprotinin outside supervised clinical or laboratory settings, and the hypersensitivity review underlines why reaction risk has been studied in monitored environments (PMID 15680884).
• Structural and modelling work: the 2025 infrared spectroscopy study is theoretical and concerns protein denaturation behaviour, not a therapeutic application (PMID 41045371).

How to Read This Literature

Three practical reading habits help when comparing aprotinin papers. First, separate study types: a thrombelastography experiment on plasma answers a different question from a clinical study in surgical patients (PMID 16430537). Second, check the population: results from orthognathic surgery patients and results from thoracic aortic surgery patients describe different risk profiles and different operations (PMID 11601817, PMID 29217251). Third, read safety reviews alongside efficacy reports, since the same compound generated both haemostatic findings and a documented hypersensitivity record (PMID 15680884, PMID 17105674).

In the United States, the FDA approved aprotinin in 1993 as the injectable product Trasylol, and the Drugs@FDA database now lists that product as discontinued. This page is not guidance. It summarises what published studies examined and reported, without recommending any action, and this page is for educational purposes only and is not medical advice; consult a licensed physician for any health question. For broader background on how peptide safety evidence is assembled, see Are Peptides Safe?.

References

• The antithrombotic and antiinflammatory mechanisms of action of aprotinin (The Annals of Thoracic Surgery, 2001)
• Forty years of clinical aprotinin use: a review of 124 hypersensitivity reactions (The Annals of Thoracic Surgery, 2005)
• Aprotinin; friend or foe? A review of recent medical literature (European Journal of Anaesthesiology, 2007)
• Aprotinin reduces blood loss and the need for transfusion in orthognathic surgery (The British Journal of Oral and Maxillofacial Surgery, 2001)
• Effects of aprotinin on plasma coagulation kinetics determined by thrombelastography: role of Factor XI (Acta Anaesthesiologica Scandinavica, 2006)
• Multiscale theoretical study of infrared spectroscopy for the thermal denaturation process of aprotinin (Journal of Molecular Modeling, 2025)
• Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19 (European Journal of Clinical Investigation, 2022)
• Aprotinin: is it prothrombotic? (Perfusion, 2001)
• Synergistic Effect of beta-alanine and Aprotinin on Mesenteric Ischemia (The Journal of Surgical Research, 2021)
• Effectiveness and Safety of Aprotinin Use in Thoracic Aortic Surgery (Journal of Cardiothoracic and Vascular Anesthesia, 2018)
• The current place of aprotinin in the management of bleeding (Anaesthesia, 2015)
• Aprotinin does not Impair Vascular Function in Patients Undergoing Coronary Artery Bypass Graft Surgery (Hormone and Metabolic Research, 2023)